Binds Lymphocytic Or Lymphocytic-like Cell Or Component Or Product Thereof (e.g., B Cell, B-lineage Bone Marrow Cell, Null Cell, Natural Killer Cell, B-lymphoblastoid Cell, B-lineage Acute Lymphoblastic Leukemia Cell, B-lymphocytic Cell-surface Antigen, Etc.) Patents (Class 530/388.73)
-
Patent number: 8551483Abstract: Described are methods of treating viral disease using compounds that block inhibitory NK cell receptors, thereby reducing their inhibition of NK cell cytotoxicity in killing infected target cells. In one embodiment, the compound is an antibody binding, for example, one or more of the human KIR2DL1, KIR2DL2, and KIR2DL3 receptors. In another embodiment, the method further comprises administering a therapeutic antibody or fusion protein which binds an antigen expressed on cells infected with the virus.Type: GrantFiled: January 6, 2006Date of Patent: October 8, 2013Assignees: Innate Pharma S.A.S., Novo Nordisk A/SInventors: Peter Andreas Nicolai Reumert Wagtmann, Francois Romagne, Joakim Glamann
-
Patent number: 8545843Abstract: The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.Type: GrantFiled: September 20, 2010Date of Patent: October 1, 2013Assignees: Genentech, Inc., Biogen Idec Inc.Inventors: John G. Curd, Antonio J. Grillo-Lopez
-
Patent number: 8546539Abstract: Disclosed are processes for producing a variant polypeptide (e.g. antibodies) having modified binding characteristics for human Fc gamma receptor IIA (CD32A) leading to increased inhibition of proinflammatory mediators while retaining binding to a target antigen via its Fv portion, which processes comprise altering the polypeptides by substitution of at least two amino acid residues at EU position 325, 326 or 328 of a human IgG CH2 region for a sequence selected from SAAF, SKAF, NAAF and NKAF. Also disclosed are molecules, particularly polypeptides, more particularly immunoglobulins (e.g. antibodies) that include a variant CDR3 region, wherein the variant CDR3 region includes at least one amino acid modified relative to a wild-type CDR3 region. The polypeptides that can be generated according to the methods of the invention are highly variable, and they can include antibodies and fusion proteins that contain an Fc region or a biologically active portion thereof.Type: GrantFiled: May 14, 2008Date of Patent: October 1, 2013Assignee: Novimmune S.A.Inventors: Greg Elson, Olivier Leger
-
Patent number: 8530627Abstract: The present invention relates to antibodies or fragments thereof that specifically bind Fc?RIIB, particularly human Fc?RIIB, with greater affinity than said antibodies or fragments thereof bind Fc?RIIA, particularly human Fc?RIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.Type: GrantFiled: July 3, 2008Date of Patent: September 10, 2013Assignee: MacroGenics, Inc.Inventors: Scott Koenig, Maria Concetta Veri
-
Patent number: 8529902Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: GrantFiled: October 17, 2003Date of Patent: September 10, 2013Assignee: Genmab A/SInventors: Jessica Teeling, Sigrid Ruuls, Martin Glennie, Jan G. J. van de Winkel, Paul Parren, Jørgen Petersen, Ole Baadsgaard, Haichun Huang
-
Patent number: 8524236Abstract: The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of CD40L. In one aspect, a monovalent anti-CD40L antibody polypeptide consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD40L, preferably without substantially agonizing CD40 and/or CD40L activity. In another aspect, the monovalent anti-CD40L antibody polypeptide is a human antibody polypeptide. The invention further encompasses methods of antagonizing CD40/CD40L interactions in an individual and methods of treating diseases or disorders involving CD40/CD40L interactions, the methods involving administering a monovalent anti-CD40L antibody polypeptide to the individual.Type: GrantFiled: September 16, 2005Date of Patent: September 3, 2013Assignee: Domantis LimitedInventors: Steven Grant, Haiqun Liu, Kevin Moulder
-
Patent number: 8524672Abstract: Disclosed are nucleic acids encoding BAFF-R polypeptides, as well as antibodies to BAFF-R polypeptides and pharmaceutical compositions including the same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided.Type: GrantFiled: August 19, 2011Date of Patent: September 3, 2013Assignee: Biogen Idec MA Inc.Inventors: Christine M. Ambrose, Jeffrey S. Thompson
-
Patent number: 8524867Abstract: Antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcyR or alters effector function as compared to the parent antibody, and methods of using the antibodies.Type: GrantFiled: August 14, 2007Date of Patent: September 3, 2013Assignee: Xencor, Inc.Inventors: Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik WeiKing Pong, John O. Richards, Eugene Alexander Zhukovsky
-
Patent number: 8524233Abstract: The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types.Type: GrantFiled: September 4, 2008Date of Patent: September 3, 2013Assignee: Biocon Limited & Centro de Immunologia MolecularInventors: Ramakrishnan Melarkode, Pradip Nair, Sundaraj David Rajkumar, Kedarnath Nanjund Sastry, Monalisa Chatterji, Laxmi Adhikary, Hema Balasubramanian, Jose Enrique Montero Casimiro, Josefa Lombardero Valladares, Rolando Perez Rodriguez
-
Patent number: 8506933Abstract: The present invention features methods of monitoring or detecting a neurological or inflammatory condition in a patient. The method comprises (1) obtaining from the patient a fluid sample from outside of a brain tissue of the patient, wherein the fluid sample contains a circulating phagocyte, and (2) detecting for one or more biomarkers (e.g., a panel of biomarkers) inside the phagocyte, wherein the biomarker is associated with the respective neurological or inflammatory condition.Type: GrantFiled: November 28, 2008Date of Patent: August 13, 2013Assignee: MSDx, Inc.Inventor: Ramesh C. Nayak
-
Patent number: 8486657Abstract: It is disclosed herein that antibodies specific for preproproteins or preproteins, which are synthesized by certain types of cells or tissues, can be used in immunohistochemistry assays to discriminate between the intracellular component of the protein (including the preproprotein, preprotein and/or proprotein forms of the protein) from the secreted component of the same protein. Accordingly, provided herein is an immunohistochemical method for specific detection of the intracellular form of a protein in a biological sample using an antibody specific for the preproprotein or preprotein form of the protein. In particular examples, the protein is albumin or an immunoglobulin light chain. Also disclosed herein are preproprotein-specific ore preprotein-specific antibodies that can be used to detect specific cell types, tissue lesions or other pathological foci and metastases by IHC. In particular, antibodies that specifically bind human preproalbumin, but do not bind the secreted form of albumin are disclosed.Type: GrantFiled: March 22, 2010Date of Patent: July 16, 2013Inventors: Xiaohong Cai, Thomas Cai
-
Patent number: 8486394Abstract: The present invention provides novel antibodies and functional fragments thereof specific for CD38, and methods of using the same for the treatment of diseases associated with CD38 expression, including hematological malignancies such as multiple myeloma.Type: GrantFiled: November 8, 2011Date of Patent: July 16, 2013Assignee: Morphosys AGInventors: Michael Tesar, Ute Jäger
-
Patent number: 8465741Abstract: The invention provides antibodies, including chimeric human antibodies, recombinant antibodies, synthetic antibodies, and the nucleic acids encoding them, and methods for making and using these immunoglobulins. The invention provides recombinant and synthetic polypeptide and nucleic acid embodiments of these polypeptides and/or antibodies. The invention also provides polypeptides comprising, or consisting of, consensus human framework regions, or “Independently Consensused Frameworks (ICFs)”, nucleic acids encoding them, and libraries and kits comprising these ICFs and/or antibodies of the invention, individually and in combinatorial libraries and combinations.Type: GrantFiled: September 14, 2007Date of Patent: June 18, 2013Assignee: MMRGlobal, Inc.Inventors: Gerhard Frey, Bruce E. Kimmel, Abraham Anderson
-
Publication number: 20130142811Abstract: The present invention relates to an antibody binding to human intercellular adhesion molecule-1 (ICAM-1) where the antibody is able to modulate the differentiation status of dendritic cells and prolong the graft survival. In addition, the present invention provides a pharmaceutical composition comprising the antibody, and method of using them for the treatment of disease.Type: ApplicationFiled: November 22, 2012Publication date: June 6, 2013Applicant: DINONA INC.Inventor: Dinona Inc.
-
Patent number: 8388973Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.Type: GrantFiled: December 30, 2010Date of Patent: March 5, 2013Assignee: Genentech, Inc.Inventors: Wesley Chang, Frederic J. de Sauvage, Dan L. Eaton, Allen J. Ebens, Jr., Gretchen Frantz, Jo-Anne S. Hongo, Hartmut Koeppen, Andrew Polson, Victoria Smith
-
Patent number: 8377435Abstract: Compositions and methods for inducing cell membrane wounding, cell permeabilization and cell killing are provided. The composition comprises a polyvalent agent that binds to a highly expressed cell surface antigen present on the surface of a cell. Preferably, the cell surface antigen is associated with the cytoskeleton of the cell. A preferred polyvalent agent is an IgM, and enhanced cell wounding and killing can be provided by the addition of a crosslinking agent. At sublethal concentrations in vivo, the cell wounding antibodies permeabilize cells and dramatically enhance response to chemotherapeutic agents, even in patients refractory to the chemotherapeutic agents.Type: GrantFiled: November 4, 2005Date of Patent: February 19, 2013Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Neelima M. Bhat, Marcia M. Bieber, Nelson N. H. Teng, Martin E. Sanders
-
Patent number: 8361472Abstract: Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject.Type: GrantFiled: August 17, 2010Date of Patent: January 29, 2013Assignee: AbGenomics Cooperatief U.A.Inventors: Rong-Hwa Lin, Chung Nan Chang, Pei-Jiun Chen, Chiu-Chen Huang
-
Patent number: 8337844Abstract: A method of treating an autoimmune disease comprising administering to a patient a therapeutically effective amount of a CD20-binding polypeptide composition comprising a combination of a modified heavy chain variable region polypeptide and a modified light chain variable region polypeptide. The combination can be (a) a modified 2B8 antibody heavy chain variable region polypeptide of SEQ ID NO: 48; and a modified 2B8 antibody light chain variable region polypeptide of SEQ ID NO: 49; or (b) a modified Leu16 antibody heavy chain variable region polypeptide of SEQ ID NO: 50; and a modified Leu16 antibody light chain variable region polypeptide of SEQ ID NO: 51.Type: GrantFiled: March 28, 2012Date of Patent: December 25, 2012Assignee: Merck Patent GmbHInventors: Francis Joseph Carr, Stephen Williams, Stephen D. Gillies
-
Patent number: 8329181Abstract: The present invention provides methods for treating a B-cell lymphoma in a human subject. The methods of the invention comprise administering to a subject in need thereof an antibody or antigen-binding fragment thereof that specifically binds human CD20. In certain embodiments, the methods of the invention are useful for treating non-Hodgkin's B-cell lymphoma.Type: GrantFiled: December 13, 2011Date of Patent: December 11, 2012Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Joel H. Martin, Li-Hsien Wang, Sean Stevens, Erin M. Allison
-
Patent number: 8323653Abstract: The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.Type: GrantFiled: September 7, 2007Date of Patent: December 4, 2012Assignee: MedImmune, LLCInventors: Melissa Damschroder, Peter Kiener, Herren Wu, William Dall'Acqua, Ronald Herbst, Anthony Coyle
-
Patent number: 8318173Abstract: The invention provides chimeric proteins and nucleic acids encoding these which can be used to generate vaccines against selected antigens. In one aspect, a chimeric protein comprises an antigen sequence and a domain for trafficking the protein to an endosomal compartment, irrespective of whether the antigen is derived from a membrane or non-membrane protein. In one preferred aspect, the trafficking domain comprises a lumenal domain of a LAMP polypeptide. Alternatively, or additionally, the chimeric protein comprises a trafficking domain of an endocytic receptor (e.g., such as DEC-205 or gp200-MR6). The vaccines (DNA, RNA or protein) can be used to modulate or enhance an immune response against any kind of antigen. In one preferred aspect, the invention provides a method for treating a patient with cancer by providing a chimeric protein comprising a cancer-specific antigen or a nucleic acid encoding the protein to the patient.Type: GrantFiled: April 5, 2002Date of Patent: November 27, 2012Assignee: The John Hopkins UniversityInventors: Thomas August, Ernesto Marques, Jr.
-
Patent number: 8303955Abstract: Provided are humanized anti-CD40 antibodies and antigen-binding fragments and methods for treating disease characterized by expression of CD40 antigen.Type: GrantFiled: May 26, 2006Date of Patent: November 6, 2012Assignee: Seattle Genetics, Inc.Inventors: Leonard G. Presta, Lori Y. O'Connell, Svetlana O. Doronina
-
Patent number: 8298540Abstract: Compounds that bind to P-Selectin Glycoprotein 1 (PSGL-1) on the surface of T cells or natural killer (NK) cells can be used to induce T cell or NK cell depletion and/or to induce T cell or NK cell apoptosis. The compounds and methods of the invention can be used to control unwanted T cell- or NK cell-mediated immune responses in conditions such as autoimmune diseases, transplant rejection, and allergic diseases.Type: GrantFiled: June 29, 2009Date of Patent: October 30, 2012Assignee: AbGenomics Cooperatief U.A.Inventors: Rong-Hwa Lin, Chung-Hsiun Wu, Pei-Ling Hsu
-
Patent number: 8287871Abstract: Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject.Type: GrantFiled: March 6, 2009Date of Patent: October 16, 2012Assignee: AbGenomics Cooperatief U.A.Inventors: Rong-Hwa Lin, Chung Nan Chang, Pei-Jiun Chen, Chiu-Chen Huang
-
Patent number: 8277810Abstract: Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.Type: GrantFiled: October 31, 2007Date of Patent: October 2, 2012Assignee: Novartis Vaccines & Diagnostics, Inc.Inventors: Li Long, Mohammad Luqman, Asha Yabannavar, Isabel Zaror, Bao-Lu Chen, Xiaofeng Lu, Sang Hoon Lee, Deborah Hurst
-
Patent number: 8246958Abstract: The invention provides methods of treatment using humanized immunoglobulins that specifically bind to alpha-4 integrin. The methods are useful for treatment of asthma, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host disease, tumor metastasis, nephritis, atopic dermatitis, psoriasis, myocardial ischemia, and acute leukocyte mediated lung injury.Type: GrantFiled: July 17, 2008Date of Patent: August 21, 2012Assignee: Elan Pharmaceuticals, Inc.Inventors: Mary M. Bendig, Olivier J. Leger, Jose Saldanha, Tarran S. Jones, Ted A. Yednock
-
Patent number: 8222376Abstract: The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, 5 upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as mono-clonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.Type: GrantFiled: January 6, 2006Date of Patent: July 17, 2012Assignees: Novo Nordisk A/S, Inmate Pharma S.A.S.Inventors: Søren Berg Padkær, Peter Reumert Wagtmann, Pieter Spee, Stefan Zahn, Kristian Kjærgaard
-
Patent number: 8206711Abstract: Chronic Lymphocytic Leukemia (CLL) may be treated with antibodies directed against the CD20 antigen.Type: GrantFiled: December 2, 2009Date of Patent: June 26, 2012Assignees: Biogen Idec Inc., Genentech, Inc.Inventors: Christine A. White, Antonio J. Grillo-Lopez, John G. Curd, Susan Desmond-Hellmann
-
Patent number: 8153125Abstract: The present invention relates to CD20 binding molecules and nucleic acid sequences encoding CD20 binding molecules. In particular, the present invention relates to CD20 binding molecules with a high binding affinity, and a low dissociation rate, with regard to human CD20. Preferably, the CD20 binding molecules of the present invention comprise light and/or heavy chain variable regions with fully human frameworks (e.g. human germline frameworks).Type: GrantFiled: May 20, 2004Date of Patent: April 10, 2012Assignee: Applied Molecular Evolution, Inc.Inventors: Jeffry D. Watkins, Julian Davies, David M. Marquis, Barrett W Allan, Brian Ondek
-
Patent number: 8148496Abstract: The present invention relates to a multivalent Fv antibody construct having at least four variable domains which are linked with each over via the peptide linkers 1, 2 and 3. The invention also concerns expression plasmids which code for such an Fv antibody construct and a method of producing the Fv antibody constructs as well as their use.Type: GrantFiled: February 6, 2009Date of Patent: April 3, 2012Assignee: Deutsches KrebsforschungszentrumInventors: Melvyn Little, Sergej Kipriyanov
-
Patent number: 8147832Abstract: A CD20-binding polypeptide composition comprising a combination of a modified heavy chain variable region polypeptide and a modified light chain variable region polypeptide. The combination can be (a) a modified 2B8 antibody heavy chain variable region polypeptide of SEQ ID NO: 48; and a modified 2B8 antibody light chain variable region polypeptide of SEQ ID NO: 49; or (b) a modified Leu16 antibody heavy chain variable region polypeptide of SEQ ID NO: 50; and a modified Leu16 antibody light chain variable region polypeptide of SEQ ID NO: 51.Type: GrantFiled: August 13, 2004Date of Patent: April 3, 2012Assignee: Merck Patent GmbHInventors: Francis Joseph Carr, Stephen Williams, Stephen D. Gillies
-
Patent number: 8138141Abstract: There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk of exhibiting sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.Type: GrantFiled: July 1, 2009Date of Patent: March 20, 2012Assignee: The Feinstein Institute for Medical ResearchInventors: Kevin J. Tracey, Haichao Wang
-
Patent number: 8124738Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to CD70 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for treating cancer, autoimmune disease, inflammation and viral infections.Type: GrantFiled: September 26, 2006Date of Patent: February 28, 2012Assignee: Medarex, Inc.Inventors: Jonathan Alexander Terret, Li-sheng Lu, David John King, Josephine M. Cardarelli, Chin Pan, Haichun Huang, Marco A. Coccia
-
Patent number: 8119775Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.Type: GrantFiled: October 2, 2008Date of Patent: February 21, 2012Assignees: University of Genoa, Innate Pharma S.A.S., Novo Nordisk A/SInventors: Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Francois Romagné, Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Stefan Zahn, Anders Svensson, Matthias Thórólfsson, Søren Berg Padkær, Kristian Kjaergaard, Pieter Spee, Michael Wilken
-
Patent number: 8101179Abstract: A murine anti-CD20 monoclonal antibody having cell growth inhibitory activities is disclosed. Cell growth inhibitory activities include apoptosis against human CD20 antigen expressing cells in culture of the CD20 antigen expressing cells without effector cells. The anti-CD20 monoclonal antibody is incorporated into chimeric anti-CD20 monoclonal antibodies in which the amino acid sequences of the variable regions of the anti-CD20 monoclonal antibody and the amino acid sequences of the constant regions of human immunoglobulin are fused. Also a humanized anti-CD20 monoclonal antibody is described which includes all of the variable region CDRs of the H chain of the anti-CD20 monoclonal antibody and all of the variable region CDRs of the L chain of the anti-CD20 monoclonal antibody and an amino acid sequence of human immunoglobulin. A nucleotide sequence encoding the amino acid sequence of the chimeric or humanized anti-CD20 monoclonal antibody can be expressed in mammalian cells.Type: GrantFiled: March 31, 2006Date of Patent: January 24, 2012Assignee: Biomedics Inc.Inventors: Masanori Numazaki, Tetsuo Nakamura, Sadakazu Usuda, Eduardo A. Padlan
-
Patent number: 8101720Abstract: An Fc variant of a parent Fc polypeptide, wherein said Fc variant exhibits altered binding to one or more Fc?Rs, wherein said Fc variant comprises at least one amino acid insertion in the Fc region of said parent Fc polypeptide.Type: GrantFiled: January 25, 2008Date of Patent: January 24, 2012Assignee: Xencor, Inc.Inventors: Gregory A. Lazar, Bassil I. Dahiyat, Wei Dang, Sher Bahadur Karki, Omid Vafa
-
Patent number: 8097703Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to CD19 with high affinity. Nucleic acid molecules encoding such CD19 antibodies, expression vectors, host cells and methods for expressing the CD19 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the CD19 antibodies are also provided. Methods for detecting CD19, as well as methods for treating various B cell malignancies, including non-Hodgkin's lymphoma, are disclosed.Type: GrantFiled: June 20, 2006Date of Patent: January 17, 2012Assignee: Medarex, Inc.Inventors: Chetana Rao-Naik, David John King, Jie Liu, Haichun Huang, David B. Passmore, Alasdair Fraser Bell, Josephine M. Cardarelli, Chin Pan, To Uyen Thi Do, Sharline Chen, Dawn M. Tanamachi
-
Patent number: 8097252Abstract: Methods and compositions are described for targeting therapeutic and diagnostic molecules to particular types of cells using targeting antibodies or other targeting moeities.Type: GrantFiled: January 6, 2011Date of Patent: January 17, 2012Assignee: Immunomedics, Inc.Inventors: William J. McBride, Chien-Hsing Chang, David M. Goldenberg, Hans J. Hansen
-
Patent number: 8088378Abstract: The present invention is directed to anti-CD79b antibody, huMA79b.v28, and compositions of matter thereof useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.Type: GrantFiled: July 15, 2008Date of Patent: January 3, 2012Assignee: Genetech Inc.Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng
-
Patent number: 8088896Abstract: The present invention provides novel antibodies and functional fragments thereof specific for CD38, and methods for using the same. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.Type: GrantFiled: October 12, 2006Date of Patent: January 3, 2012Assignee: Morphosys AGInventors: Michael Tesar, Ute Jäger
-
Patent number: 8088383Abstract: Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity when the antibody binds a CD40 antigen on a normal human B cell, exhibits antagonist activity when the antibody binds a CD40 antigen on a malignant human B cell, and can exhibit antagonist activity when the antibody binds a CD40 antigen on a normal human B cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of malignant human B cells.Type: GrantFiled: September 27, 2010Date of Patent: January 3, 2012Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Keting Chu, Lorianne K. Masuoka
-
Patent number: 8063187Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.Type: GrantFiled: May 30, 2008Date of Patent: November 22, 2011Assignee: Xencor, Inc.Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
-
Patent number: 8044180Abstract: The present invention relates to antibodies or fragments thereof that specifically bind Fc?RIIB, particularly human Fc?RIIB, with greater affinity than said antibodies or fragments thereof bind Fc?RIIA, particularly human Fc?RIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.Type: GrantFiled: July 3, 2008Date of Patent: October 25, 2011Assignee: MacroGenics, Inc.Inventors: Scott Koenig, Maria Concetta Veri
-
Publication number: 20110243931Abstract: The present application is directed to the combination therapy of a type I and a type II anti-CD20 antibody for the treatment of cancer, especially of CD20 expressing cancer.Type: ApplicationFiled: August 20, 2008Publication date: October 6, 2011Inventors: Thomas Friess, Christian Klein, Pablo Umana
-
Publication number: 20110230647Abstract: The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells, and identifies HVEM as interacting with BTLA. Methods and compositions for modulating BTLA-mediated signaling and interfering with the interaction of BTLA and HVEM for therapeutic, diagnostic and research purposes are also provided.Type: ApplicationFiled: December 23, 2010Publication date: September 22, 2011Applicant: THE WASHINGTON UNIVERSITYInventors: Kenneth M. Murphy, Theresa L. Murphy, John R. Sedy, Michelle A. Hurchla Pyles, Norihiko Watanabe, Jianfei Yang
-
Patent number: 8012484Abstract: The present invention relates to a method for treating recurrent tumor metastases following liver resection that includes administration of an effective amount of an agonist of A2A adenosine receptors (ARs).Type: GrantFiled: March 25, 2008Date of Patent: September 6, 2011Assignee: University of Virginia Patent FoundationInventors: Joel M. Linden, Courtney M. Lappas, Victor H. Engelhard
-
Patent number: 8012470Abstract: According to the invention there is described a method for ex vivo immunization of humans and animals comprising the following steps of: a) isolating autologous tumor cells; b) treating the tumor cells to prevent the survival thereof following reinfusion; c) incubating the thus treated tumor cells with intact heterologous bispecific and/or trisepcific antibodies showing the following properties: ?—binding to a T cell; ?—binding to at least one antigen on a tumor cell; ?—binding, by their Fc portion (in the case of bispecific antibodies), or by a third specificity (in the case of trispecific antibodies) to Fc receptor-positive cells.Type: GrantFiled: July 20, 2005Date of Patent: September 6, 2011Assignee: Helmholtz Zentrum Munchen Deutsches Forschungszentrum fur Gesundheit und Umwelt (GmbH)Inventors: Horst Lindhofer, Hans-Joachim Kolb, Reinhard Zeidler, Georg Bornkamm
-
Patent number: 7939282Abstract: Compositions and methods for detecting sepsis by contacting a subject-derived sample with a ligand that binds to GRK and determining the concentration of GRK in the sample. An increase in the concentration of GRK compared to that of a normal, healthy control sample indicates that the subject from which the sample is obtained is suffering from or at risk of developing sepsis.Type: GrantFiled: October 20, 2005Date of Patent: May 10, 2011Assignee: Rhode Island HospitalInventors: Loren D. Fast, Yow-Pin Lim
-
Patent number: 7927596Abstract: The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of DC40L. in one aspect, a monovalent anti-CD40L antibody polypeptide consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of DC40L, preferably without substantially agonizing CD40 activity. In another aspect, the monovalent anti-CD40L antibody polypeptide is a human antibody polypeptide. The invention further encompasses methods of antagonizing CD40/CD40L interactions in an individual and methods of treating diseases or disorders involving CD40/DC40L interactions, the methods involving administering a monovalent anti-CD40L antibody polypeptide to the individual.Type: GrantFiled: May 1, 2009Date of Patent: April 19, 2011Assignee: Domantis LimitedInventors: Steven Grant, Haiqun Liu, Kevin Moulder
-
Patent number: 7902338Abstract: The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases. In more particular embodiments, the humanized anti-CD19 antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels. In a particularly preferred embodiment, the substitutions comprise a the substitution of serine for phenylalanine at Kabat residue 91 in the human framework region in the hA19 VH sequence.Type: GrantFiled: November 7, 2008Date of Patent: March 8, 2011Assignee: Immunomedics, Inc.Inventors: Hans J. Hansen, Zhengxing Qu, David M. Goldenberg